About Transcription initiation factor IIE subunit beta
Transcription initiation factor IIE subunit beta (GTF2E2) is a protein
from Homo sapiens identified by UniProt accession
P29084, 291 residues long.
MolForge cross-references it against 0 known binders and
53 disease associations.
Target properties
| Protein name | Transcription initiation factor IIE subunit beta |
|---|
| UniProt accession | P29084 |
|---|
| Gene | GTF2E2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 291 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (53)
Diseases linked to this target (Open Targets).
- trichothiodystrophy · score 0.67
- HIV infection · score 0.58
- neurodegenerative disease · score 0.48
- mean corpuscular hemoglobin concentration · score 0.22
- mean corpuscular volume · score 0.21
- mean corpuscular hemoglobin · score 0.21
- genetic disorder · score 0.18
- clear cell renal carcinoma · score 0.17
- high density lipoprotein cholesterol measurement · score 0.16
- open-angle glaucoma · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P29084-F1 | alphafold | PREDICTED | 68.16 | — |
Amino-acid sequence (291 residues)
MDPSLLRERE LFKKRALSTP VVEKRSASSE SSSSSSKKKK TKVEHGGSSG SKQNSDHSNG SFNLKALSGS SGYKFGVLAK IVNYMKTRHQ RGDTHPLTLD EILDETQHLD IGLKQKQWLM TEALVNNPKI EVIDGKYAFK PKYNVRDKKA LLRLLDQHDQ RGLGGILLED IEEALPNSQK AVKALGDQIL FVNRPDKKKI LFFNDKSCQF SVDEEFQKLW RSVTVDSMDE EKIEEYLKRQ GISSMQESGP KKVAPIQRRK KPASQKKRRF KTHNEHLAGV LKDYSDITSS K
Explore Transcription initiation factor IIE subunit beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets